FTC v. Endo: Does No-Authorized Generic Agreement Meet Supreme Court Pay-For-Delay Test?
This article was originally published in The Pink Sheet Daily
FTC alleges Endo's Opana ER patent settlement with Impax gave it time to introduce a reformulated product; agency also challenges side deal on Parkinson's disease drug and Endo's Lidoderm settlement with Watson.
You may also be interested in...
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.
Justices rule FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers, but Actavis pledges to continue defending these deals.